How a big biotech’s start-up gamble went wrong
Behind the Money
00:00
Introduction
Francis D'Souza, the CEO of Illumina at the time, spoke on an investor relations call in September 2020. The acquisition valued at $8 billion was presented as a way for Illumina to corner a new market in the realm of cancer screening and detection. PIGIM has over 1,400 investment professionals relentlessly research in pursuit of long-term goals.
Transcript
Play full episode
